# Chronic Urticaria Treatment Comparison Tables
## Based on AAAAI/ACAAI JTFPP Systematic Reviews (2024-2025)

---

## TABLE 1: TREATMENT EFFICACY COMPARISON

| Treatment | Urticaria Activity (UAS7) | Angioedema | Quality of Life | Evidence Certainty | Category |
|-----------|---------------------------|------------|-----------------|-------------------|----------|
| **BIOLOGICS** |||||
| Omalizumab 300mg Q4W | MD -8.37 ⬇️⬇️⬇️ | +8.75% more free weeks | MD -12.68 ⬇️⬇️⬇️ | **HIGH** | Most Effective |
| Remibrutinib | MD -7.65 ⬇️⬇️⬇️ | +15.00% more free weeks | MD -11.65 ⬇️⬇️⬇️ | **HIGH** | Most Effective |
| Dupilumab | MD -6.01 ⬇️⬇️ | **NO DATA** ❓ | MD -9.73 ⬇️⬇️ | Moderate | Likely Most Effective |
| Low-dose omalizumab | MD -5.25 ⬇️⬇️ | +5.08% (NS) | MD -8.23 ⬇️⬇️ | HIGH/Moderate | Intermediate |
| Barzolvolimab | MD -7.18 ⬇️⬇️⬇️ | Not reported | Not reported | Low | Phase 2 - Promising |
| Benralizumab | MD -2.84 ↔️ | -2.46% (NS) | MD -0.28 ↔️ | Low | Not Effective |
| Tezepelumab | MD -2.00 ↔️ | +1.39% (NS) | MD -4.69 ↔️ | Low | Not Effective |
| **BTK INHIBITORS** |||||
| Fenebrutinib | MD -5.75 ⬇️⬇️ | Not reported | Not reported | Low | May Be Effective |
| Rilzabrutinib | MD -2.89 ↔️ | Not reported | Not reported | Low | May Not Be Effective |
| **IMMUNOSUPPRESSANTS** |||||
| Cyclosporine | MD -10.18 ⬇️⬇️⬇️ | Not reported | MD -8.25 ⬇️⬇️ | Low | May Be Most Effective |
| Azathioprine | MD -8.07 ⬇️⬇️⬇️ | Not reported | Not reported | Low | May Be Effective |
| Mycophenolate* | MD -15.01 ⬇️⬇️⬇️⬇️ | Not reported | Not reported | Very Low | Non-RCT Data |
| Sulfasalazine* | MD -10.65 ⬇️⬇️⬇️ | Not reported | Not reported | Very Low | Non-RCT Data |
| Methotrexate | MD -4.03 ↔️ | Not reported | MD -4.03 ↔️ | Very Low | Disappointing |
| Hydroxychloroquine | MD -5.98 ⬇️⬇️ | Not reported | MD -12.14 ⬇️⬇️⬇️ | Low | May Be Effective |
| Dapsone | MD -3.91 ↔️ | Not reported | MD -9.24 ⬇️⬇️ | Low | May Not Be Effective |
| **CORTICOSTEROIDS** |||||
| Systemic (short-course) | Improved | Not reported | Not reported | Moderate | NNT 7 (refractory) |
| Topical | ~50% wheal reduction | Not reported | Not reported | Low | Limited Role |
| **ADD-ON THERAPY** |||||
| LTRAs | MD -5.04 ⬇️ | Limited data | MD -3.51 ⬇️ | Moderate | Below MID |

*Non-randomized data only
⬇️ = Improvement; ↔️ = No meaningful difference; ❓ = No data

---

## TABLE 2: SAFETY PROFILE COMPARISON

| Treatment | Any AE (RD) | Serious AE | Discontinuation | Safety Certainty | Safety Category |
|-----------|-------------|------------|-----------------|------------------|-----------------|
| **BIOLOGICS** |||||
| Omalizumab (any dose) | +4% | No difference | No difference | **HIGH** | Favorable |
| Remibrutinib | +3% | Likely no difference | No difference | Low-Moderate | Uncertain |
| Dupilumab | 0% | Likely no difference | No difference | **HIGH** | Favorable |
| Benralizumab | -2% | Likely no difference | Likely no difference | Low | Favorable |
| Tezepelumab | +13% | Likely no difference | Not reported | Low | Uncertain |
| Barzolvolimab | +8% | Not reported | Not reported | Low | Uncertain |
| **BTK INHIBITORS** |||||
| Fenebrutinib | +3% | Not reported | Not reported | Low | Uncertain |
| Rilzabrutinib | +12% | Not reported | Not reported | Low | Uncertain |
| **IMMUNOSUPPRESSANTS** |||||
| **Cyclosporine** | **+21%** ⚠️ | Limited data | Limited data | Low | **May Be Most Harmful** |
| Azathioprine | +18% | Not reported | Not reported | Very Low | Uncertain |
| Dapsone | +32% | Not reported | Not reported | Very Low | Uncertain |
| Methotrexate | +1% | No difference | May increase | Low | May Be Favorable |
| Mycophenolate* | -36% | +3% more | Limited data | Very Low | Uncertain |
| Sulfasalazine* | -20% | +2% more | Limited data | Very Low | Uncertain |
| **CORTICOSTEROIDS** |||||
| Systemic (short-course) | NNH 9 (~15% more) | Not reported | Not reported | Moderate | Use Cautiously |
| Topical | No difference | No difference | Not applicable | **HIGH** | Favorable |
| **ADD-ON THERAPY** |||||
| LTRAs | No difference | FDA boxed warning | NNH 77 | Moderate | FDA Warning |

*Non-randomized data only
⚠️ = Caution warranted

---

## TABLE 3: NUMBER NEEDED TO TREAT (NNT) / NUMBER NEEDED TO HARM (NNH)

| Treatment | NNT for Response | NNH for Any AE | Net Benefit | Context |
|-----------|------------------|----------------|-------------|---------|
| **Systemic Corticosteroids** ||||
| - AH-refractory patients | **7** | 9 | Favorable | Short-term flares |
| - AH-responsive patients | 45 | 9 | Unfavorable | Avoid |
| **LTRAs** ||||
| - Urticaria activity | 8 | No increase | Marginal | Below MID |
| - Neuropsychiatric AEs | — | 161 | Small risk | FDA warning |
| **Omalizumab 300mg Q4W** ||||
| - Urticaria activity | ~3-4 | No increase | Very Favorable | First-line biologic |
| **Cyclosporine** ||||
| - Urticaria activity | ~3-4 | ~5 | Mixed | Reserve for refractory |

---

## TABLE 4: CLINICAL DECISION FACTORS

| Factor | Omalizumab | Dupilumab | Remibrutinib | Cyclosporine |
|--------|------------|-----------|--------------|--------------|
| **Efficacy Certainty** | HIGH | Moderate | HIGH | Low |
| **Safety Certainty** | HIGH | HIGH | Low | Low |
| **Angioedema Data** | ✅ Proven | ❌ No data | ✅ Proven | ❌ Limited |
| **Route** | SC injection | SC injection | Oral | Oral |
| **Self-administration** | Yes | Yes | Yes | Yes |
| **Comorbidity Benefits** |||||
| - Food allergy | ✅ FDA approved | — | — | — |
| - Atopic dermatitis | — | ✅ FDA approved | — | — |
| - CRSwNP | — | ✅ FDA approved | — | — |
| - Asthma | ✅ FDA approved | ✅ FDA approved | — | — |
| **Monitoring Required** | Minimal | Minimal | TBD | **Yes** (renal, BP, lipids) |
| **Long-term Safety Data** | Extensive | Good | Limited | Well-characterized |
| **Cost** | $$$$  | $$$$ | TBD | $$ |
| **FDA Approval (CSU)** | ✅ Yes | ✅ Yes (2024) | ❌ Not yet (2025) | ❌ Off-label |

---

## TABLE 5: FAILED/DISCONTINUED TREATMENTS

| Treatment | Trial | Reason for Failure | Evidence |
|-----------|-------|-------------------|----------|
| Ligelizumab | PEARL-1, PEARL-2 | No superiority vs omalizumab | Development discontinued |
| Benralizumab | ARROYO | No therapeutic effect | Not effective |
| Tezepelumab | INCEPTION | Limited efficacy for CSU | May not differ from placebo |
| Quilizumab | QUAIL | No therapeutic effect | Not effective |
| Canakinumab | URTICANA | No efficacy | MD 0.02 (no effect) |
| Rilonacept | Cold urticaria trial | Not effective for cold urticaria | Negative results |

---

## TABLE 6: EVIDENCE GAPS BY TREATMENT

| Treatment | Missing Evidence | Priority for Future Research |
|-----------|------------------|------------------------------|
| **Dupilumab** | Angioedema outcomes | HIGH — Critical gap |
| **Remibrutinib** | Long-term safety | HIGH — New drug |
| **LTRAs** | LTRA + AH vs 4× AH | HIGH — Clinically relevant |
| **Topical CS** | CSU trials (not skin prick) | Moderate |
| **Systemic CS** | Optimal dose/duration | Moderate |
| **Mycophenolate** | Any RCT data | Moderate |
| **Sulfasalazine** | Any RCT data | Moderate |
| **High-dose omalizumab** | Comparative trials | Moderate |
| **Combination biologics** | Any trials | Low (practical barriers) |

---

## TABLE 7: GRADE CERTAINTY SUMMARY BY OUTCOME

| Outcome | HIGH Certainty | MODERATE Certainty | LOW Certainty | VERY LOW Certainty |
|---------|----------------|-------------------|---------------|-------------------|
| **Urticaria Activity** | Omalizumab, Remibrutinib, Low-dose OMA | Dupilumab, Systemic CS | Cyclosporine, Azathioprine, Hydroxychloroquine, TCS | Methotrexate, Mycophenolate, Sulfasalazine |
| **Angioedema** | Omalizumab, Remibrutinib | Low-dose OMA | Benralizumab, Tezepelumab | — |
| **Quality of Life** | Omalizumab, Remibrutinib | Low-dose OMA | Dupilumab, Cyclosporine | — |
| **Safety (Any AE)** | — | Omalizumab | Remibrutinib, Dupilumab, Cyclosporine | Azathioprine, Dapsone |
| **Serious AEs** | Omalizumab | All others | — | Mycophenolate, Sulfasalazine |
| **Discontinuation** | Omalizumab, Dupilumab, Remibrutinib | — | — | — |

---

*Tables based on AAAAI/ACAAI JTFPP Systematic Reviews 2024-2025*
*For use in Chronic Urticaria Clinical Reasoning Tool*
*Last Updated: December 2025*
